OR WAIT 15 SECS
December 22, 2015.
The treatment market for gastric and gastroesophageal junction adenocarcinoma (gastric cancer) will experience rapid growth, from $1.13 billion in 2014 to $4.39 billion by 2024, representing CAGR of 14.6%, according to GlobalData.
The company’s latest report states that the rise will be driven primarily by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and lengthier treatment duration.
GlobalData analyst Fenix Leung says that growth will be strongest across the five major European markets, as sales will increase from $301 million in 2014 to $1.49 billion by 2024, at a robust CAGR of 17.3%.
Leung notes that “Roche is expected to remain a strong player in the gastric cancer market with its new therapy Perjeta in the pipeline. However, it only targets a minority of patients, who are HER2-positive, which limits sales potential. Overall, GlobalData expects Roche to lose its leading position in the market to Eli Lilly, which owns the recently-approved antiangiogenic agent Cyramza.”